Stem cell transplantation for the management of primary systemic amyloidosis
- 1 November 2002
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 113 (7) , 549-555
- https://doi.org/10.1016/s0002-9343(02)01208-1
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 PatientsBlood, 1998
- AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTSBritish Journal of Haematology, 1997
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineNew England Journal of Medicine, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Current concepts on the pathogenesis of systemic amyloidosisNephrology Dialysis Transplantation, 1996
- Response rates and survival in primary systemic amyloidosisBlood, 1991
- Primary systemic amyloidosis: comparison of melphalan and prednisone versus placeboBlood, 1978
- TREATMENT OF "PRIMARY" RENAL AMYLOIDOSIS WITH MELPHALANThe Lancet, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958